Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients

Barbui, T.; De Stefano, V.; Carobbio, A.; Iurlo, A.; Alvarez-Larran, A.; Cuevas, B.; Ferrer Marin, F.; Vannucchi, A. M.; Palandri, F.; Harrison, C.; Sibai, H.; Griesshammer, M.; Bonifacio, M.; Elli, E. M.; Trotti, C.; Koschmieder, S.; Carli, G.; Benevolo, G.; Ianotto, J. -C.; Goel, S.; Falanga, A.; Betti, S.; Cattaneo, D.; Arellano-Rodrigo, E.; Mannelli, L.; Vianelli, N.; Doyle, A.; Gupta, V.; Wille, K.; Tremblay, D.; Mascarenhas, J.

doi:10.1038/s41375-021-01279-1

In the Philadelphia-negative myeloproliferative neoplasms (MPN), the major burden of disease is the elevated risk of thrombosis [1]. Moreover, MPN patients are concomitantly prone to bleeding [1], making antithrombotic therapy challenging. Regarding atrial fibrillation (AF), very scarce data are available about treatment outcomes with vitamin-K antagonists (VKAs) or direct oral anticoagulants (DOACs) [2, 3]. On the other hand, VKAs partially prevent recurrent venous thromboembolism (VTE), and the incidence of either recurrent thrombosis and major bleeding is still unacceptable high [4].

Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients / Barbui T., De Stefano V., Carobbio A., Iurlo A., Alvarez-Larran A., Cuevas B., Ferrer Marin F., Vannucchi A.M., Palandri F., Harrison C., Sibai H., Griesshammer M., Bonifacio M., Elli E.M., Trotti C., Koschmieder S., Carli G., Benevolo G., Ianotto J.-C., Goel S., et al.. - In: LEUKEMIA. - ISSN 0887-6924. - ELETTRONICO. - 35:(2021), pp. 2989-2993. [10.1038/s41375-021-01279-1]